A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263.
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2017
At a glance
- Drugs GSK 1292263 (Primary) ; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Acronyms GPR Met Add-on
- Sponsors GlaxoSmithKline
- 12 Jun 2012 Effects of GSK 1292263 on lipid parameters presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
- 28 Jun 2011 Results presented at the 71st Annual Scientific Sessions of the American Diabetes Association.
- 28 May 2010 New trial record
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History